

**S10 Table.** Contributions of direct evidence in the entire network

| Outcomes                     | Drug A  | Drug B | No. of trials | Contribution to the network, % |
|------------------------------|---------|--------|---------------|--------------------------------|
| <b>HbA1c</b>                 | SGLT-2i | PLA    | 2             | 14.3                           |
|                              | DPP-4i  | PLA    | 8             | 17.8                           |
|                              | GLP-1   | PLA    | 4             | 11.2                           |
|                              | TZD     | PLA    | 4             | 2.8                            |
|                              | AGI     | PLA    | 2             | 6.3                            |
|                              | SGLT-2i | Met    | 1             | 11.4                           |
|                              | DPP-4i  | AGI    | 1             | 5.3                            |
|                              | DPP-4i  | Basal  | 1             | 9.9                            |
|                              | GLP-1   | TZD    | 1             | 10.8                           |
|                              | TZD     | Met    | 1             | 10.3                           |
| <b>FPG</b>                   | SGLT-2i | PLA    | 2             | 20.9                           |
|                              | DPP-4i  | PLA    | 7             | 15.1                           |
|                              | GLP-1   | PLA    | 3             | 12.9                           |
|                              | TZD     | PLA    | 2             | 5.8                            |
|                              | AGI     | PLA    | 2             | 9.2                            |
|                              | SGLT-2i | Met    | 1             | 18.7                           |
|                              | DPP-4i  | AGI    | 1             | 4.2                            |
|                              | TZD     | Met    | 1             | 13.2                           |
| <b>Body weight</b>           | SGLT-2i | PLA    | 1             | 21.0                           |
|                              | DPP-4i  | PLA    | 3             | 21.0                           |
|                              | GLP-1   | PLA    | 3             | 19.7                           |
|                              | TZD     | PLA    | 1             | 1.6                            |
|                              | SGLT-2i | Met    | 1             | 12.6                           |
|                              | DPP-4i  | AGI    | 1             | 12.6                           |
|                              | GLP-1   | TZD    | 1             | 11.6                           |
| <b>Hypoglycemia</b>          | SGLT-2i | PLA    | 2             | 11.3                           |
|                              | DPP-4i  | PLA    | 7             | 20.1                           |
|                              | GLP-1   | PLA    | 4             | 9.0                            |
|                              | TZD     | PLA    | 5             | 13.0                           |
|                              | AGI     | PLA    | 2             | 5.6                            |
|                              | SGLT-2i | Met    | 1             | 5.6                            |
|                              | DPP-4i  | AGI    | 1             | 5.5                            |
|                              | DPP-4i  | Basal  | 1             | 10.6                           |
|                              | GLP-1   | TZD    | 1             | 8.1                            |
|                              | TZD     | Met    | 1             | 11.2                           |
| <b>Serious adverse event</b> | SGLT-2i | PLA    | 2             | 20.2                           |
|                              | DPP-4i  | PLA    | 7             | 19.9                           |
|                              | GLP-1   | PLA    | 3             | 11.8                           |
|                              | TZD     | PLA    | 1             | 11.8                           |
|                              | AGI     | PLA    | 1             | 11.6                           |

|         |       |   |      |
|---------|-------|---|------|
| SGLT-2i | Met   | 1 | 11.8 |
| DPP-4i  | AGI   | 1 | 1.2  |
| DPP-4i  | Basal | 1 | 11.8 |

Note: HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist; AGI,  $\alpha$ -glucosidase inhibitor; TZD, thiazolidinedione; Met, metformin; Basal, basal (long acting) insulin, PLA, placebo.